Shire Effort to Take Roche’s Hemlibra Off Market Fails (Correct)

Shire Plc failed to persuade a U.S. judge to pull a Roche Holding AG hemophilia drug off the market for all but a subset of patients while a patent-infringement lawsuit is pending.

Roche’s unit, Genentech Inc., began selling Hemlibra in November and Shire sued in May, claiming the drug infringes its patent for an antibody that increases blood-clotting activity. Shire asked the judge to force Hemlibra off the market, saying it unfairly steals sales from Shire’s own treatments sold by its Baxalta Inc. unit.

Judge Timothy Dyk rejected Shire’s arguments, which carved out an exception for patients who have developed ...